Every letter we have printed

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

You write that no trial has measured strength. There are observational cohorts with grip strength data. Why do you insist on randomised measurement?

You describe biased agonism as "legitimate and probably important" and then decline to say which molecules are biased in which direction. That is a strange place to stop.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

Your accumulation table gives 2.0 for a seven-day half-life at weekly dosing. I make it 2.0 as well, but I would point out that this assumes complete absorption of each dose, which for subcutaneous peptides is a generous assumption.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

I want to push back on the ginger paragraph. You describe the evidence as transferred from pregnancy and chemotherapy, which is accurate, and then include it in the table anyway. Either it belongs or it does not.

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

You state that fourteen of twenty suppliers report an MS identity test. Does that count reports supplied to you on request, or only what appears on the certificate a customer receives?

On your point about D-amino acids: chiral amino-acid analysis after hydrolysis is not exotic and several contract laboratories offer it. The obstacle is that hydrolysis itself racemises a few per cent of most residues, so the method has a blank problem, and interpreting a low-level D content is genuinely difficult rather than merely expensive.

Your article says a matching mass does not confirm a sequence, which is correct, and then rather implies that vendors are trading on the ambiguity. I run analytical services and I would put it differently: we report what we measured, in the words our clients ask for. If the Journal wants the word confirmed retired, write to the buyers, not to us.

I would add one omission to your six lines: the date and nature of the last calibration. A parts-per-million figure from an instrument last calibrated a fortnight ago is a different claim from one calibrated that morning with an internal standard.

You give the glutamine-to-lysine difference as 0.036 daltons and say it needs an orbital trap. In practice you also need the two species to be chromatographically separated or present in a sensible ratio, because at one per cent of the parent intensity the minor peak sits on the shoulder of the isotope envelope regardless of resolving power.

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

As an anaesthetist I read the perioperative section with interest and one objection. You frame disclosure as the patient obligation. In my experience the failure is more often ours: the pre-assessment questionnaire in my own institution did not include these drugs until eighteen months after the first guidance appeared.

Eleven days in customs, and you describe it as a structural feature rather than a scandal. Why the restraint? A shipper advertising a cold chain that demonstrably does not survive a routine examination is making a claim it cannot support.

Your section on freezing reconstituted solution stops short of the obvious question, which I will therefore ask. If a phosphate buffer shifts pH substantially on freezing, does that not mean the freezer is actively worse than the refrigerator for a buffered formulation, rather than merely unproven?

You draw a distinction between retest date and expiry date and then say suppliers use the wrong word. Which word do you think they should use, given that most of them have no study behind either?

My mother is eighty-one and on a low dose for her diabetes. Her weight is down nine kilograms and she now struggles to get out of a low chair, which she did not eighteen months ago. Nobody has measured anything. I do not know whether this is the drug, the weight loss, or being eighty-one, and neither does anybody I have asked.

The soft-tissue artefact point in your bone section is underplayed. In a patient losing twenty per cent of body mass the change in overlying tissue is well outside the range the calibration was validated over, and the published analyses do not report a sensitivity analysis for it. That is not a caveat, it is a gap.

Three vendors have now sent me marketing material claiming their product preserves lean mass during GLP-1 treatment, two of them citing your publication as a source for the underlying composition figures. You may want to know that.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

Your piece treats the one-quarter rule as discredited and then quotes fractions of one third and two fifths from the substudies as though those were more solid. They are group means from a hundred and forty people. Physician, heal thyself.

I supply research peptides and I want to push back on the specification column point. We sell from a catalogue of six hundred products. Writing a meaningful individual specification for each would take a year of somebody’s time, and a generic one would be exactly the decorative limit your article criticises. What would you actually have us do?

VendorInvestigate does not measure anything and you have grouped it with three laboratories under the heading independent testing. That is exactly the conflation your article says the market makes.

On the archive point: a public record of submissions by vendor would be gamed within a month. Vendors would submit under the names of resellers, or through intermediaries, and the archive would show a distribution as selected as the current one but with a veneer of completeness.

You note that no service offers sterility testing and that it takes fourteen days. Worth saying more plainly: a purity certificate and a sterility assurance are not merely different tests, they are different disciplines with different facilities, and no amount of chromatography will ever bear on it.

Nine years buying research chemicals and I had never once looked at the date of manufacture. I checked eleven certificates in my drawer this evening. Four do not carry one.

The composite test table you print as a model is unrealistic. No research supplier is going to run headspace GC and ion chromatography on every lot at these price points, and publishing an aspirational document as a benchmark just makes real certificates look worse than they are.

You put every documentary finding to the company before publication, which is admirable and also means you are letting companies that do not reply escape coverage entirely. Silence should have a cost.

A technical query on your identity row: you specify 4111.1 Da monoisotopic with a tolerance of ±10 ppm, which is 0.04 daltons. Is that not tighter than most contract laboratories will commit to on a peptide of that size?

You note that symptom burden does not predict weight outcome. This is the single most useful sentence I have read about this treatment. I spent four months believing that feeling well meant it was not working and considered increasing my dose on that basis alone.

Your incidence tables are from the licensed products. I use compounded material at a concentration that does not match any pen. Are the figures transferable at all?

You give the reference change value for ALT as about sixty per cent, which strikes me as so large as to make routine monitoring of it pointless. Is that your position?

As a biomedical scientist I would add one point to your reference-interval section: many laboratories do not derive their own intervals at all. They adopt the manufacturer interval for the platform, which was established in a population that may have nothing to do with the one being tested. The interval on the report can be a document about a different country.

I stopped treatment fifteen weeks ago and my panel is worse than I expected. I had a panel at five weeks that looked fine and I had assumed I had escaped. Your point about the twelve-week timing was the explanation nobody offered me.

I run analytical services and I object to the framing of your blind comparison. You bought our cheapest tier, published the number it produced alongside a competitor’s most thorough package, and called the result a spread. It is not a spread. It is three different products, priced accordingly, and your own table says so two columns to the right of the headline figure.

I submitted a vial to one of these services last year, got a result three points below what the vendor advertised, and did not know what to do with it. Your article explains why: I had one measurement on one vial, no method comparison, and no way to know if my vial was representative. I still do not know what to do with it, but I understand the shape of not knowing.